On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Alexander Drilon

ResearcherPublications, citations & collaboration network

Alexander Drilon is a researcher indexed in ScholarIQ from OpenAlex & ORCID.

How many works does Alexander Drilon have?

ScholarIQindexed works

Alexander Drilon has 1,448 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Alexander Drilon have?

ScholarIQcitation count

Alexander Drilon has 40,274 citations in the OpenAlex counts ScholarIQ stores.

What is the h-index of Alexander Drilon?

ScholarIQh-index

Alexander Drilon has an h-index of 93 in OpenAlex.

What is the i10-index of Alexander Drilon?

ScholarIQi10-index

Alexander Drilon has an i10-index of 297 in OpenAlex.

What is the ORCID of Alexander Drilon?

ScholarIQorcid

The ORCID for Alexander Drilon is on the source record.

What is the OpenAlex record for Alexander Drilon?

ScholarIQopenalex

The OpenAlex for Alexander Drilon is on the source record.

What are the most-cited papers on Alexander Drilon?

ScholarIQmost cited works
Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children
Alexander Drilon, Theodore W. Laetsch, Shivaani Kummar, Steven G. DuBois, Ulrik Lassen, George D. Demetri, Michael J. Nathenson, Robert C. Doebele, Anna F. Farago, Alberto S. Pappo, Brian Turpin, Afshin Dowlati, Marcia S. Brose, Leo Mascarenhas, Noah Federman, Jordan Berlin, Wafik S. El‐Deiry, Christina S. Baik, John F. Deeken, Valentina Boni, Ramamoorthy Nagasubramanian, Matthew H. Taylor, Erin R. Rudzinski, Funda Meric‐Bernstam, Davendra Sohal, C. Patrick, Luis E. Raez, Jaclyn F. Hechtman, Ryma Benayed, Marc Ladanyi, Brian B. Tuch, Kevin Ebata, Scott Cruickshank, Nora Ku, Michael C. Cox, Douglas S. Hawkins, David S. Hong, David M. Hyman
New England Journal of Medicine. 20182,775 CitationsOPEN ACCESS
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
Robert C. Doebele, Alexander Drilon, Luis Paz‐Ares, Salvatore Siena, Alice T. Shaw, Anna F. Farago, Collin M. Blakely, Takashi Seto, Byoung Chul Cho, Diégo Tosi, Benjamin Besse, Sant P. Chawla, Lyudmila Bazhenova, John C. Krauss, Young Kwang Chae, Minal Barve, Ignacio Garrido‐Laguna, Stephen V. Liu, Paul Conkling, Thomas John, Marwan Fakih, Darren Sigal, Herbert H. Loong, Gary L. Buchschacher, Pilar Garrido, Jorgé Nieva, Conor Steuer, Tobias R. Overbeck, Daniel W. Bowles, Elizabeth Fox, Todd Riehl, Edna Chow‐Maneval, Brian Simmons, Na Cui, Ann Johnson, Susan Eng, Timothy R. Wilson, George D. Demetri
The Lancet Oncology. 20191,776 CitationsOPEN ACCESS
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J. Mazieres, Alexander Drilon, Amélie Lusque, Laurent Mhanna, Alexis B. Cortot, Laura Mezquita, Alesha A. Thai, Céline Mascaux, S. Couraud, Rémi Veillon, Michel M. van den Heuvel, Joel W. Neal, Nir Peled, Martin Früh, Terry L. Ng, V. Gounant, Sanjay Popat, Joachim Diebold, Joshua K. Sabari, Viola W. Zhu, Sacha I. Rothschild, Paolo Bironzo, Alex Martínez‐Martí, Alessandra Curioni‐Fontecedro, Rafael Rosell, Mickaël Lattuca-Truc, Marcel Wiesweg, Benjamin Besse, Benjamin Solomon, Fabrice Barlési, Robert D. Schouten, Heather A. Wakelee, D. Ross Camidge, Gérard Zalcman, Silvia Novello, Sai‐Hong Ignatius Ou, Julie Milia, Oliver Gautschi
Annals of Oncology. 20191,375 CitationsOPEN ACCESS
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
David S. Hong, Steven G. DuBois, Shivaani Kummar, Anna F. Farago, Catherine M. Albert, Kristoffer Staal Rohrberg, Cornelis M. van Tilburg, Ramamoorthy Nagasubramanian, Jordan Berlin, Noah Federman, Leo Mascarenhas, Birgit Geoerger, Afshin Dowlati, Alberto S. Pappo, Stefan Bielack, François Doz, Ray McDermott, Jyoti D. Patel, Russell J. Schilder, Makoto Tahara, Stefan M. Pfister, Olaf Witt, Marc Ladanyi, Erin R. Rudzinski, Shivani Nanda, Barrett H. Childs, Theodore W. Laetsch, David M. Hyman, Alexander Drilon
The Lancet Oncology. 20201,009 CitationsOPEN ACCESS
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
Alexander Drilon, Geoffrey R. Oxnard, Daniel Shao-Weng Tan, Herbert H. Loong, Melissa L. Johnson, Justin F. Gainor, Caroline E. McCoach, Oliver Gautschi, Benjamin Besse, Byoung Chul Cho, Nir Peled, Jared Weiss, Yu-Jung Kim, Yuichiro Ohe, Makoto Nishio, Keunchil Park, Jyoti D. Patel, Takashi Seto, Tomohiro Sakamoto, Ezra Y. Rosen, Manisha H. Shah, Fabrice Barlési, Philippe A. Cassier, Lyudmila Bazhenova, Filippo de Braud, Elena Garralda, Vamsidhar Velcheti, Miyako Satouchi, Kadoaki Ohashi, Nathan A. Pennell, Karen L. Reckamp, Grace K. Dy, Jürgen Wolf, Benjamin Solomon, Gerald S. Falchook, Kevin Ebata, Michele Nguyen, Binoj C. Nair, Edward Y. Zhu, Luxi Yang, Xin Huang, Elizabeth Olek, S. Michael Rothenberg, Kōichi Goto, Vivek Subbiah
New England Journal of Medicine. 2020842 CitationsOPEN ACCESS

Related on ScholarIQ

470M+ articles · free account